Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Opportunities in In Situ Hybridization

This article was originally published in Start Up

Executive Summary

In-situ hybridization (ISH) is a powerful method of genetic testing. But it has not yet found a place in the clinical laboratory. In addition to technical, patent and regulatory obstacles, participants will confront a fragmented market composed currently of high-priced, low-volume tests. Many scientists believe ISH will have an important role in the clinical laboratory, while others see it mostly as an interim technology likely to be superseded by easier-to-use DNA chips.

Related Content

Vysis Preps For Prime Time





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts